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Introduction:  Screening  methods  have  become  increasingly  important  due  to  the  growing  num-
ber of  patients  suspected  of  having  obstructive  sleep  apnea  (OSA)  being  referred  to  sleep  clinics.
The Lausanne  NoSAS  (Neck  circumference,  Obesity,  Snoring,  Age,  Sex)  score  test  is  a  simple,
efficient,  and  easily  employed  tool  enabling  identification  of  individuals  at  risk  for  the  disease.
The score  ranges  from  0  to  17  and  the  patient  has  a  high  probability  of  OSA  if  they  have  a  NoSAS
score of  8  or  higher.
Objectives:  To  evaluate  the  performance  of  the  NoSAS  score  as  a  screening  tool  for  the  diagnosis
of OSA  in  a  sleep  clinic.
Methods:  Prospectively,  for  12  months,  we  included  all  the  patients  referred  by  primary  care
physicians  to  our  sleep  unit  for  clinical  evaluation  who  had  undergone  in-lab  polysomnography
(PSG) and  completed  the  NoSAS  score.  This  test  assigns  4  points  for  a  neck  circumference  of
more than  40  cm,  3  points  for  a  body-mass  index  of  25  kg/m2 to  less  than  30  kg/m2 or  5  points
for having  a  body-mass  index  of  30  kg/m2 or  more,  2  points  for  snoring,  4  points  for  being  older
than 55  years  of  age  and  2  points  for  being  male.
Results:  Of  the  294  patients,  70.7%  were  male,  aged  53.5  ±  12.1  years,  with  a  neck  circumfer-
ence of  41.0  ±  3.6  cm  and  a  BMI  of  30.8  ±  5.1  kg/m2.  OSA  was  present  in  84.0%  of  the  patients,
34.8% with  moderate  OSA  and  36.4%  severe  OSA.  Using  the  NoSAS  model  for  the  prediction  of  all∗ Corresponding author.
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OSA,  moderate/severe  OSA  and  severe  OSA,  the  area  under  the  ROC  (Receiver  Operating  Char-
acteristic)  was  0.770  (IC95%:  (0.703;  0.837),  p  <  0.001),  0.746  (IC95%:  (0.691;  0.802),  p  <  0.001)
and 0.686  (IC95%:  (0.622;  0.749),  p  <  0.001),  respectively,  thus  confirming  the  diagnostic  ability
of the  NoSAS  model.
With  a  NoSAS  score  ≥7,  the  sensitivity  and  positive  predictive  value  (PPV)  were  94.3%  and
87.6% for  all  OSA,  94.9%  and  62.8%  for  moderate/severe  OSA  and  100%  and  33.8%  for  severe  OSA,
respectively.  With  the  same  cut-off,  the  negative  predictive  value  (NPV)  for  moderate/severe
and severe  OSA  were  67.9%  and  100%,  respectively.  Each  increase  in  the  NoSAS  score  was  asso-
ciated with  an  increase  in  the  probability  of  OSA,  reaching  a  97%  OSA  probability  for  a  score  of
17.
Conclusions:  The  NoSAS  score  showed  high  sensitivity  and  PPV  for  OSA  with  specificity  and
diagnostic accuracy  steadily  increasing  with  higher  scores.  Furthermore,  a  low  score  showed
high predictive  value  for  the  exclusion  of  moderate/severe  OSA.  Overall,  our  results  suggest
that, in  primary  care,  this  score  can  be  a  powerful  tool  for  stratifying  and  prioritizing  patients
in the  diagnosis  of  OSA.  Nevertheless,  more  studies  are  needed  to  evaluate  the  efficacy  of
this score  in  hospital  health  care,  in  younger  populations,  with  a  predominance  of  female  and
non-obese  individuals  or  in  cardiovascular  disease.
© 2019  Sociedade  Portuguesa  de  Pneumologia.  Published  by  Elsevier  España,  S.L.U.  This  is  an






























































bstructive  sleep  apnea  syndrome  (OSA)  is  characterized
y  obstruction  of  the  upper  respiratory  tract  leading  to
ncreased  respiratory  effort  with  inadequate  ventilation.
he  obstruction  is  caused  by  the  collapse  of  the  pharynx  due
o  the  decrease  of  the  muscle  tone  that  occurs  during  sleep;
ndividuals  that  present  risk  factors  are  predisposed  to  this
ituation  occurring.  These  episodes  are  inevitably  accompa-
ied  by  desaturation,  increased  activity  of  the  sympathetic
ervous  system  with  frequent  arousals.  Snoring  and  daytime
leepiness  are  the  main  complaints  and  observed  apnea  is
he  most  specific  symptom.
Individuals  with  hidden  disease  are  at  high  risk  of  medi-
al  comorbidities  and  of  road  accidents  due  to  excessive
leepiness.  There  is  an  independent  association  of  OSA
ith  increased  morbidity  and  mortality  due  to  metabolic
isorders,  neurovascular  and  cardiovascular  disease,  and
mpaired  neurocognitive  function,  even  if  asymptomatic.1--3
The  prevalence  of  this  pathology  depends  significantly
n  the  population  studied  and  the  definition  of  OSA  crite-
ia  (study  methodology  and  threshold  of  apnea  hypopnea
ndex  (AHI)  used).4,5 According  to  Heinzer  et  al.,  the  preva-
ence  is  about  23.4%  in  women  and  49.7%  in  men.6 Estimates
how  that  the  male/female  ratio  ranges  from  2:1  to  4:1.  It
an  appear  in  all  age  groups,  however,  studies  show  that
omen  have  a  higher  incidence  in  the  age  group  above  65
ears,  prevalence  increasing  after  menopause,  while  in  men
t  occurs  between  45  and  64  years  of  age.7
Screening  methods  have  become  increasingly  important
ue  to  the  growing  number  of  patients  suspected  of  hav-
ng  obstructive  sleep  apnea  being  referred  to  sleep  clinics.
he  difficulty  of  diagnosis  of  this  pathology  is  related  to  the
vailability  and  accessibility  of  cardiorespiratory  sleep  stud-
es  (laboratory  diagnosis).  Consequently,  prioritization  and




 simple  and  reliable  method  of  screening  certain  popu-
ations,  namely  high-risk  groups,  is  needed.  The  choice  of
creening  method  will  depend  on  its  ability  to  achieve  a
pecific  objective:  to  include  patients  with  OSA  for  appropri-
te  sleep  testing;  to  detect  those  with  more  severe  disease
acilitating  early  diagnosis  and  treatment;  and  to  exclude
atients  without  OSA  or  without  severe  OSA,  whose  evalua-
ion  and  treatment  is  less  urgent.
Numerous  clinical  prediction  models  have  been  devel-
ped  based  on  clinical,  demographics  and  anthropometric
ariables.8,9 A  recently  proposed  screening  method  is  the
ausanne  NoSAS  Score  test  (Appendix  A),  a  simple,  efficient,
nd  easily  employed  tool  enabling  identification  of  individu-
ls  at  risk  for  the  disease.10 This  score  assess  5  parameters:
eck  circumference,  Obesity,  Snoring,  Age,  Sex  and  assigns  4
oints  for  having  a  neck  circumference  of  more  than  40  cm,
 points  for  having  a  body-mass  index  of  25  kg/m2 to  less
han  30  kg/m2 or  5  points  for  having  a  body-mass  index  of
0  kg/m2 or  more,  2  points  for  snoring,  4  points  for  being
lder  than  55  years  of  age  and  2  points  for  being  male.  The
core  ranges  from  0  to  17  and  the  patient  has  a  high  prob-
bility  of  OSA  if  they  have  a  NoSAS  score  of  8  or  higher.
hus,  it  helps  to  identify  individuals  at  risk  for  the  disease
nd  rule  out  others  without  risk,  with  a  negative  predic-
ive  value  (NPV)  of  90%  and  98%  in  two  ethnically  different
opulation-based  cohorts.10
ethods
bjectivehe  present  study  aimed  to  evaluate  the  performance  of  the
oSAS  score  as  a  screening  tool  for  the  diagnosis  of  OSA  in  a

















































Validation  of  NoSAS  score  as  a  screening  tool  for  obstructive
Study  design
Prospective  study,  12  months  in  duration,  beginning  in  Jan-
uary  2017,  we  considered  consecutively  all  patients  with
suspicious  sleep  disorder,  referred  by  primary  care  physi-
cians  to  our  sleep  unit  for  clinical  evaluation  and  who
underwent  in-lab  polysomnography  (PSG).
During  the  clinical  consultation,  every  patient  was  asked
if  they  accepted  participation  in  the  study,  regardless  of
the  reasons  for  being  referred,  which  included  referral  for
isolated  symptoms  or  clinical  suspicion  of  a  specific  sleep
disorder  (e.g.  OSA,  insomnia,  parasomnia).
All  patients  included  were  required  to  complete  the
NoSAS  questionnaire,10 with  information  concerning  neck
circumference,  body  mass  index  (BMI),  snore,  age  and
gender,  ultimately  collected  by  a  clinician.  We  also  evalu-
ated  other  parameters  namely  Epworth’s  score,  tiredness,
observed  apnea  and  high  blood  pressure  (blood  pressure
>140/90  mmHg  or  make  treatment  for  hypertension).
The  research  staff  did  not  interfere  with  the  interpreta-
tion  or  completion  of  the  questionnaires.
Patients  previously  diagnosed  with  OSA,  those  unable
to  read  and/or  write,  additional  diagnoses  obtained
throughout  the  sleep  study  (like  central  sleep  apnea  and
obesity/hypoventilation  syndrome)  and  all  cases  of  techni-
cal  error  during  data  collection,  were  excluded  from  the
study.
Sleep  studies,  scoring  and  diagnosis
At  the  specialized  sleep  center,  all  patients  underwent  a
standard  PSG,  using  the  patient’s  usual  bedtime  overnight.
A  standardized  setting  made  up  of  surface  electrodes  was
used  and  included:  electrocardiogram,  electroencephalo-
gram,  electrooculogram,  submental  and  lower  limb  EMG.
Besides  this  data,  additional  information  was  collected
regarding  oronasal  airflow  (thermistor  and  pressure  sensor),
thoracic  and  abdominal  respiratory  effort,  pulse  oximetry,
snoring  and  body  position  sensoring.  A  certified  PSG  techni-
cian  scored  the  PSG  recordings,  ensuring  correct  assembly,
under  the  supervision  of  a  sleep  physician  who  reviewed  and
validated  the  final  reports.  The  sleep  physician  and  techni-
cian  were  both  blinded  to  the  study  report  (both  clinical
information  and  NoSAS).  The  scoring  was  done  manually,
following  the  recommendations  of  the  American  Academy
of  Sleep  Medicine.11 Apnea  was  defined  as  a  decrease  of
at  least  90%  of  airflow  from  baseline,  lasting  10  second
or  longer.  Hypopnea  was  defined  as  a  decrease  of  at  least
30%  of  airflow  from  baseline,  lasting  10  second,  associated
with  either  an  arousal  or  a  ≥3%  O2 saturation  decrease.  The
mean  number  of  apneas  and  hypopneas  per  hours  of  sleep
(apnea--hypopnea  index  [AHI])  was  calculated.  Both  diag-
nosis  and  severity  of  OSA  were  classified  based  upon  the
AHI:  >5--15/h  --  mild,  >15--30/h  --  moderate,  and  >30/h  --
severe.11,12
Additional  diagnoses  obtained  throughout  the  sleep  study
were  defined  accordingly  to  the  International  Classification
of  Sleep  disorders-third  edition.13 However,  our  study  was
exclusively  focused  on  OSA,  so  all  other  diagnoses  were
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tatistical  analysis
tatistical  analysis  was  made  using  the  IBM  SPSS
®
statistical
rogram,  version  25  (the  Statistical  Package  for  the  Social
ciences).
The  categorical  variables  were  described  with  frequen-
ies  and  percentages  and  the  quantitative  variables  with
ean,  median,  standard  deviation,  maximum  and  minimum.
ll  associations  between  the  presence  of  OSA  and  each  of  the
ossible  risk  factors  were  established  using  logistic  regres-
ion,  which  estimated  their  odds  ratios  (ORs).
To  evaluate  the  performance  of  the  NoSAS  score  in
redicting  OSA,  sensitivity,  specificity,  negative  predictive
alues  (NPVs)  and  positive  predictive  values  (PPVs)  were
stimated  for  different  AHI  cut-offs.
To  measure  the  diagnostic  ability  of  the  NoSAS  score  for
ifferent  AHI  cut-offs,  we  also  determined  the  area  under
he  receiver  operating  characteristic  (ROC)  curve  and  the
alue  of  the  score  where  both  sensitivity  and  specificity
aximized.
For  the  evaluation  of  the  influence  of  the  NoSAS  score  in
he  estimation  of  the  probabilities  of  OSA  severity,  an  ordinal
egression  model  was  fitted  with  the  logit  link  function.  The
ald  test  was  considered  significant  when  its  p-value  did  not
xceed  0.05.
esults
f  the  294  patients,  70.7%  were  male,  aged  53.5  ±  12.1
ears,  with  a  neck  circumference  of  41.0  ±  3.6  cm  and  a
MI  of  30.8  ±  5.1  kg/m2. OSA  was  present  in  84.0%  of  the
atients,  28.8%  with  mild  OSA,  34.8%  moderate  and  36.4%
evere.
Descriptive  summary  statistics,  NoSAS  characteristics  and
omparison  of  OSA  and  non-OSA  groups  are  displayed  in
able  1.  Although  greater  in  the  OSA  group,  tiredness  was
he  only  characteristic  which  were  not  significantly  different
etween  the  OSA  and  non-OSA  group.
Using  the  NoSAS  model  for  the  prediction  of  all  OSA,  mod-
rate/severe  OSA  and  severe  OSA,  the  area  under  the  ROC
urve  (AUC)  was  0.770  (IC95%:  (0.703;  0.837),  p  <  0.001),
.746  (IC95%:  (0.691;  0.802),  p  <  0.001)  and  0.686  (IC95%:
0.622;  0.749),  p  <  0.001),  respectively,  thus  confirming  the
iagnostic  ability  of  the  NoSAS  model.
The  sensitivity,  specificity,  PPV,  and  NPV  for  all  OSA,
oderate/severe  OSA,  and  severe  OSA  are  summarized  in
able  2.  With  a  NoSAS  score  ≥7,  the  sensitivity  and  positive
redictive  value  (PPV)  were  94.3%  e  87.6%  for  all  OSA,  94.9%
nd  62.8%  for  moderate/severe  OSA  and  100%  and  33.8%  for
evere  OSA,  respectively.  With  the  same  cut-off,  the  neg-
tive  predictive  value  (NPV)  for  all  OSA,  moderate/severe
SA  and  severe  OSA  were  50%,  67.9%  and  100%,  respectively.
s  the  score  increased  from  7  to  12,  the  specificity  and  PPV
ncreased  continuously  from  29.8%  to  83%  and  87.6%  to  94.7%
or  all  OSA,  16.1%  to  74.6%  and  62.8%  to  80%  for  moder-
te/severe  OSA,  and  13.7%  to  57.8%  and  33.8%  to  42.7%  for
evere  OSA,  respectively.The  predicted  probabilities  of  having  OSA,  moder-
te/severe  OSA,  and  severe  OSA  are  shown  in  Table  3.  As
oSAS  score  increased  from  2  to  17,  the  probability  of  hav-
ng  OSA,  moderate/severe  OSA,  and  severe  OSA  increased
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Table  1  Summary  statistics  of  the  patient  population  and  comparison  of  OSA  and  non  OSA  group.




N  =  247
(84.0%)
No
N  =  47  (16.0%)
Age  (years)  1.062  (1.032;  1.093)  <0.001
Average ±  SD  55.81  ±  11.43  47.49  ±  13.06
Median(mín;  máx)  56  (20;  82)  47  (23;  77)
Tiredness  (n)  (%)
Yes  150  (60.7)  22  (46.8)  1.757  (0.938;  3.291)  0.078  (NS)
No 97  (39.3)  25  (53.2)  1
Observed  apnea  (n)  (%)
Yes  179  (72.5)  16  (34.0)  5.100  (2.623;  9.915)  <0.001
No 68  (27.5)  31  (66.0)  1
Pessure (high  blood)
Yes  150  (60.7)  14  (29.8)  3.645  (1.855;  7.161)  <0.001
No 97  (39.3)  33  (70.2)  1
Epworth’s  Score 1.067  (1.004;  1.135) 0.036
Average ±  SD 10.97  ±  5.35 9.15  ±  5.19
Median(mín;  máx) 11  (1;  24) 8  (2;  20)
Minimum  saturation  0.731  (0.657;  0.814)  <0.001
Average ±  SD  78.41  ±  10.63  88.30  ±  4.34
Median  (mín;  máx)  81.0  (0.0;  92.0)  90.0  (74.0;  95.7)
Neck circ.  >  40  cm  (n)  (%)
Yes  150  (60.7)  9  (19.1)  6.529  (3.023;  14.104)  <0.001
No 97  (39.3)  38  (80.9)  1
Obesity (n)  (%)  <0.001
BMI <  25  14  (5.7)  13  (27.7)  1
BMI 25--30  102  (41.3)  21  (44.6)  4.510  (1.854;  10.973)  0.001
BMI ≥  30  131  (53.0)  13  (27.7)  9.357  (3.634;  24.096)  <0.001
Snoring (n)  (%)
Yes  241  (97.6)  42  (89.4)  4.782  (1.396;  16.380)  0.013
No 6  (2.4)  5  (10.6)  1
Gender (n)  (%)
Female  63  (25.5)  23  (48.9)  1
Male 184  (74.5)  24  (51.1)  2.799  (1.477;  5.305)  0.002
NoSAS 1.310  (1.196;  1.435)  <0.001
Average ±  SD  12.35  ±  3.51  8.43  ±  3.86




















a Teste de Wald.
Abbreviations: OR = odds ratio; CI = Confidence Interval; BMI: body
ontinuously  from  35%  to  97%,  12%  to  85%  and  5%  to  53%,
espectively.  This  trend,  present  in  all  groups  is  illustrated
n  Fig.  1.
The  predicted  probabilities  of  having  OSA  of  a  specific
everity  are  illustrated  in  Fig.  2.  With  each  incremental
ncrease  in  the  score  from  0  to  7,  the  probability  of  having
o  sleep  apnea  diminished,  while  the  probability  of  having
ild,  moderate,  or  severe  sleep  apnea  increased  continu-usly.  With  any  score  greater  than  7,  only  the  probability
f  having  moderate  or  severe  sleep  apnea  increased.  With  a
core  greater  than  13,  only  the  probability  of  having  severe





s index; OSA: obstructive sleep apnea; NS: not significant.
iscussion
his  study  shows  that,  in  a  population  referred  to  a  sleep
edicine  clinic,  a  NoSAS  score  ≥7  has  high  sensitivity  (94.3%)
nd  PPV  (87.6%)  for  the  diagnosis  of  OSA  and  that  the  greater
he  NoSAS  score,  reflecting  a higher  cumulative  score  of
nown  risk  factors,  the  greater  the  probability  of  sleep
pnea,  particularly  moderate  to  severe  sleep  apnea  (Fig.  2).
he  probability  of  OSA  for  a  score  of  7  is  67%  and  increases
ontinuously  to  73%,  78%,  86%,  91%,  95%  and  97%  with  a  step-
ise  increase  of  the  NoSAS  score  to  8,  9,  11,  13,  15  and
7.  This  performance  is  due  to  the  increasing  probability
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Table  2  Predictive  parameters  of  each  NoSAS  score  cut-offs  for  different  AHI  levels  (n,  number  of  patients  in  the  AHI  group
who scored  the  NoSAS  score  indicated  or  higher;  percentage  out  of  the  294  patients).
All  OSA  (AHI  >  5)
NoSAS  score  cut-off  N  (%)  Sensitivity  Specificity  PPV  NPV
≥1 247  (84.0) 100  2.1  85.5  100
≥3 247 (84.0) 100  10.6 85.5 100
≥4 246  (83.7) 99.6 10.6 85.4 83.3
≥5 241  (82.0)  97.6  21.3  86.7  62.5
≥6 235  (79.9)  95.1  27.7  87.4  52.0
≥7 233  (79.3)  94.3  29.8  87.6  50.0
≥8 216  (73.5)  87.4  40.4  88.5  38.0
≥9 210  (71.4)  85.0  44.7  89.0  36.2
≥11 190  (64.6)  76.9  55.3  90.0  31.3
≥12a 142  (48.3)  57.5  83.0  94.7  27.1
≥13 141  (48.0)  57.1  83.0  94.6  26.9
≥15 91  (31.0)  36.8  95.7  97.8  22.4
≥17 42  (16.7)  17.0  100  100  18.7
18 0  (0.0)  0.0  100  --  16.0
Moderate/severe  OSA  (AHI  >  15)
NoSAS  score  cut-off  N  (%)  Sensitivity  Specificity  PPV  NPV
≥1  176  (59.9)  100  0.8  60.0  100
≥3 176  (59.9)  100  4.2  60.9  100
≥4 176  (59.9)  100  5.1  61.1  100
≥5 173  (58.8)  98.3  11.0  62.2  81.3
≥6 169  (57.5)  96.0  15.3  62.8  72.0
≥7 167  (56.8)  94.9  16.1  62.8  67.9
≥8 158  (53.7)  89.8  27.1  64.8  64.0
≥9 155  (52.7)  88.1  31.4  65.8  63.8
≥11 142  (48.3)  80.7  41.5  67.3  59.0
≥12 120  (40.8)  68.2  74.6  80.0  61.1
≥13a 120  (40.8)  68.2  75.4  80.5  61.4
≥15 79  (26.9)  44.9  88.1  84.9  51.7
≥17 41  (13.9)  23.3  99.2  97.6  46.4
18 0  (0.0)  0.0  100  --  40.1
Severe OSA  (AHI  >  30)
NoSAS  score  cut-off  N  (%)  Sensitivity  Specificity  PPV  NPV
≥1  90  (30.6)  100  0.5  30.7  100
≥3 90  (30.6)  100  2.5  31.1  100
≥4 90  (30.6)  100  2.9  31.3  100
≥5 90  (30.6)  100  7.8  32.4  100
≥6 90  (30.6)  100  12.3  33.5  100
≥7 90  (30.6)  100  13.7  33.8  100
≥8 85  (28.9)  94.4  22.1  34.8  90.0
≥9 85  (28.9)  94.4  26.0  36.0  91.4
≥11 76  (25.9)  84.4  33.8  36.0  83.1
≥12 64  (21.8)  71.1  57.8  42.7  81.9
≥13a 64  (21.8)  71.1  58.3  43.0  82.1
≥15 44 (15.0)  48.9  76.0  47.3  77.1
≥17 22 (7.5) 24.4  90.2  53.4  73.0
18 0  (0.0)  0.0  100  --  69.4
a Cut-off value that maximizes both sensitivity and specificity.
Abbreviations:  AHI: Apnea--Hypopnea Index; OSA: obstructive sleep apnea; PPV: positive predictive value; NPV: negative predictive
value.
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Table  3  Predicted  probabilities  of  each  NoSAS  score  for  different  AHI  levels  (n,  number  of  patients  in  the  AHI  group  who  scored
the NoSAS  score  indicated;  percentage  out  of  the  294  patients).
NoSAS  score  cut-off  All  OSA  (AHI  >  5)  Mod./severe  OSA  (AHI  >  15)  Severe  OSA  (AHI  >  30)
N  (%)  Probability  N  (%)  Probability  N  (%)  Probability
0  0  (0.0)  0.24  0  (0.0)  0.08  0  (0.0)  0.03
2 0  (0.0) 0.35 0  (0.0)  0.12  0  (0.0)  0.05
3 1  (0.4) 0.41 0  (0.0) 0.15  0  (0.0)  0.06
4 5  (2.0) 0.48 3  (1.7) 0.19 0  (0.0) 0.08
5 6  (2.4)  0.55  4  (2.3)  0.23  0  (0.0)  0.09
6 2  (0.8)  0.61  2  (1.1)  0.28  0  (0.0)  0.11
7 17  (6.9)  0.67  9  (5.1)  0.33  5  (5.6)  0.13
8 6  (2.4)  0.73  3  (1.7)  0.39  0  (0.0)  0.16
9 20  (8.1)  0.78  13  (7.4)  0.45  9  (10.0)  0.18
11 48  (19.4)  0.86  22  (12.5)  0.57  12  (13.3)  0.25
12 1  (0.4)  0.89  0  (0.0)  0.63  0  (0.0)  0.29
13 50  (20.2)  0.91  41  (23.3)  0.68  20  (22.2)  0.34
15 49  (19.8)  0.95  38  (21.6)  0.78  22  (24.4)  0.43
17 42  (17.0)  0.97  41  (23.3)  0.85  22  (24.4)  0.53




















All OSA (AHI > 5)
Mod./severe OSA (AHI > 15)
Severe OSA (AHI > 30)
Interpolation line
Figure  1  Plot  of  predicted  probabilities  for  different  AHI  lev-





























































et  al.,  shows  8  as  a threshold  and  the  score  was  definedigure  2  Plot  of  predicted  probabilities  for  different  OSA
everities  with  the  corresponding  NoSAS  score.
f  moderate  to  severe  OSA  for  each  score  above  7,  reach-
ng  a  predicted  probability  of  57%,  68%,  78%  and  85%  for  a
core  of  11,  13,  15  and  17  (Table  3),  respectively.  Moreover,
 score  lower  than  7  showed  discriminative  power  to  exclude





nd  81.3%  for  a  score  of  7,  6  and  5,  respectively.  The  AUC
as  consistently  high  confirming  the  diagnostic  ability  of
he  NoSAS  model  for  all  OSA  severities.  Furthermore,  tired-
ess  was  statistically  similar  between  the  OSA  and  non-OSA
roups,  although  tending  to  be  greater  and  more  prevalent
n  the  OSA  group,  reflecting  tiredness  as  an  equally  common
omplaints  among  patients  with  various  sleep  disorders  and
iseases  of  other  organs.
Owing  to  the  relatively  high  prevalence  of  undiagnosed
SA  and  its  comorbidities,  a  trustworthy  screening  tool  is
eeded  and  mandatory  for  a  prompt  prediction  of  OSA.
 quick  and  reliable  screening  test  can  enable  clinicians
ithin  a  clinical  context  to  make  more  informed  diagnostic
ecisions,  particularly  when  stratifying  patients  for  unrec-
gnized  OSA  and  triage  for  further  diagnostic  assessment
nd  treatment.  Where  they  can  be  used  and  scored  eas-
ly,  as  part  of  routine  daily  practice,  questionnaires  can  be
ppropriate  tools  for  that  purpose.  Moreover,  analysis  of
he  questionnaire  performance  in  specific  populations  can
rovide  clinicians  with  a  set  of  predictive  parameters  for
ifferent  levels  of  OSA  severity,  which  can  be  used  as  a  cru-
ial  guide  for  diagnostic  and  therapeutic  decisions.  In  our
tudy  the  present  results  show  that  the  NoSAS  questionnaire,
an  add  great  value  and  be  a  very  useful  and  powerful  tool
n  primary  care.  On  the  basis  of  its  ability  to  discriminate
articipants  with  clinically  significant  disorder,  its  PPV,  and
ts  NPV,  NoSAS  score  can  be  a  very  useful  tool  for  triaging
atients  depending  on  their  score:  score  of  0--5  --  low  proba-
ility  of  OSA,  particularly  moderate  to  severe  OSA;  score  ≥7
robable  OSA;  score  ≥12  high  probability  of  OSA,  specifically
oderate  to  severe  OSA.
Numerous  questionnaires  and  other  clinical  screening
ools  for  OSA  have  been  analyzed  previously.  The  study
f  derivation  and  validation  of  NoSAS  score  of  Marti-Solers  positive  if  it  was  greater  than  or  equal  to  8  points  and
egative  if  it  was  less  than  8  points,  on  the  basis  of  its



















Validation  of  NoSAS  score  as  a  screening  tool  for  obstructive
disorder.10 This  study  shows  an  AUC  of  0.74,  a  PPV  of  47%,
an  NPV  of  90%  and  the  NoSAS  score  performed  significantly
better  than  did  the  STOP-Bang  (AUC  0.67)  and  Berlin  (AUC
0.63)  scores.10 In  our  cohort,  we  propose  7  as  a  threshold  and
obtained  an  even  higher  performance  with  the  AUC  0.770,
a  PPV  of  87.6%  and  a  NPV  of  67.9%.
Moreover,  there  are  some  papers  that  evaluated  NoSAS
that  are  worth  mentioning.  According  Guichard  et  al.,  NoSAS
was  similar  to  Berlin  and  significantly  better  than  STOP-Bang
questionnaire  (AUC  was  0.72  for  NoSAS,  0.66  for  STOP-Bang
and  0.69  for  the  Berlin  score).14 A  study  of  Tan  et  al.,
also  evaluated  NoSAS  score  and  compared  its  performance
to  the  STOP-Bang  and  Berlin  questionnaires.15 The  sensi-
tivity,  specificity,  and  NPV  and  PPV  of  the  NoSAS  score  to
predict  severe  sleep  disorder  breathing  (defined  as  an  AHI
of  ≥30  events/h),  were  69.2%,  73.1%,  95.2%,  and  23.7%,
respectively.16 They  concluded  that  its  performance  was
similar  to  the  STOP-Bang  and  Berlin  questionnaires,  with
AUC  values  of  all  three  questionnaires  clustered  around
0.682--0.748.16 According  Lye  et  al.,  the  sensitivity,  speci-
ficity,  and  NPV  and  PPV  of  the  NoSAS  score  to  predict
severe  OSA  (AHI  ≥  30  events/h)  was  64.3%,  70.0%,  63.8%  and
70.4%,  respectively.16 The  AUC  of  NoSAS  score  (0.724)  was
higher  than  Epworth  Sleepiness  Scale  (ESS)  (0.544).16 They
concluded  that  overall  the  NoSAS  score  performed  better
than  the  ESS.16 Moreover,  according  Cicero  et  al.,  a  high
NoSAS  score  was  associated  with  increased  arterial  stiffness,
reduced  renal  function  and  increased  mean  arterial  pressure
in  a  large  cohort  of  healthy  individuals.17 Although  this  study
did  not  evaluate  NoSAS  accuracy  and  do  not  suggest  a  causal
link  between  OSA  and  cardiovascular  disease,  it  also  showed
clinical  relevance  in  using  this  score  to  identify  individuals
who  probably  have  OSA  and  a  higher  cardiovascular  risk.17
In  reference  to  the  validation  of  a  Portuguese  version  of
the  STOP-Bang  in  primary  care,  by  Rebelo-Marques  et  al.,
using  this  model  for  the  prediction  of  OSA,  the  diagnostic
ability  of  the  STOP-Bang  was  relatively  superior  to  NoSAS
score  (the  AUC  was  0.847).18
In  conclusion,  our  results  agree  with  and  support  the
original  data  from  Marti-Soher  et  al.,10 and  can  help  to
implement  and  generalize  its  use  in  primary  care.
However,  this  study  has  limitations  that  must  be  men-
tioned.  The  fact  that  our  sample  consisted  mainly  of  obese
men  with  an  average  age  of  over  50  years  may  have  condi-
tioned  our  results.
Conclusions
The  NoSAS  score  showed  high  sensitivity  and  PPV  for  OSA
with  specificity  and  diagnostic  accuracy  which  steadily
increased  with  higher  scores.  Furthermore,  a  low  score
showed  high  predictive  value  for  the  exclusion  of  moder-
ate/severe  OSA.  Overall,  our  results  suggest  that  this  score
is  simple,  efficient,  and  easy  to  implement,  it  enables  iden-
tification  of  individuals  at  risk  of  the  disease  and  can  help
primary  care  clinicians  to  decide  which  patients  to  investi-
gate  further  with  a  nocturnal  recording.  So  this  score  can
be  a  powerful  tool  in  primary  care  for  stratifying  and  prior-
itizing  patients  in  the  diagnosis  of  OSA,  depending  on  their
score:  score  of  0--5  --  low  probability  of  OSA,  particularly
moderate  to  severe  OSA;  score  ≥7  probable  OSA;  score  ≥12p  apnea  269
igh  probability  of  OSA,  particularly  moderate  to  severe
SA.  Nevertheless,  more  studies  are  needed  to  evaluate
he  efficacy  of  this  score  in  hospital  health  care,  in  younger
opulations,  with  a  predominance  of  female  and  non-obese
ndividuals  or  in  cardiovascular  disease.
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ppendix A. NoSAS score
.  Neck  circumference  >40  cm  --  4  points
.  Obesity
-  BMI  25  kg/m2 to  <30  kg/m2 --  3  points
-  BMI  ≥30  kg/m2 --  5  points
.  Snoring  -- 2 points
.  Age  >55  years  -- 4  points
.  Sex:  male  -- 2 points
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